5 Min Read
There is no evidence to suggest COVID-19 vaccines will cause an “exponential rise” in deaths at the end of the year.
This and other false claims were made by two individuals in a popular video on Facebook (here). The most damaging claims will be addressed in this article.
PHASE THREE TRIALS
A woman in the video claims the COVID-19 vaccine “is an experimental injection” that “hasn’t had phase three trials” (timestamp 0.40). This is false.
All vaccines approved in the UK completed large phrase-three studies to gather significant data of the vaccine’s safety and efficacy, as outlined by Oxford University’s Vaccine Knowledge Project (here). The results of these trials can be found online: for Pfizer/BioNTech (here), Moderna (here) and Oxford/AstraZeneca (here).
30 december 2020 kl 08:01
Working with the UK government, first vaccinations to begin early in the New Year
Regulatory interactions continue around the world for next approvals
AstraZeneca s COVID-19 vaccine has been approved for emergency supply in the UK, with the first doses being released today so that vaccinations may begin early in the New Year.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has provided authorisation for emergency supply of COVID-19 Vaccine AstraZeneca, formerly AZD1222, for the active immunisation of individuals 18 years or older. The authorisation recommends two doses administered with an interval of between four and 12 weeks. This regimen was shown in clinical trials to be safe and effective at preventing symptomatic COVID-19, with no severe cases and no hospitalisations more than 14 days after the second dose.
AstraZeneca s COVID-19 vaccine has been approved for emergency supply in the UK, with the first doses being released today so that vaccinations may begin early in the New Year. The UK Medicines and Healthcare products Regulatory Agency (MHRA) has provided authorisation for emergency supply of COVID-19 Vaccine AstraZeneca, formerly AZD1222, for the active immunisation of individuals 18 years or older. The authorisation recommends two doses administered with an interval of between four and 12 weeks. This regimen was shown in clinical trials to be safe and effective at preventing symptomatic COVID-19, with no severe cases and no hospitalisations more than 14 days after the second dose.
QP check sheets and Pfizer/BioNTech provide these to the
MHRA for each batch along with the
QP certificates of conformance.
QP certification must take into NIBSC
certification process, as this in itself does not imply release to market.
QP certification declares: (i) compliance with all stages of EU
GMP (where non-compliant, a gap analysis must be performed, and captured on the
QP checksheet), and (ii) that the batch has been manufactured as per the dossier supplied (currently Emergency Use Authorisation).
A certificate of conformance with
GMP and the conditions of this authorization must be generated by the releasing
QP and supplied to the onward supply chain.
Women urged to delay vaccine if they plan on getting pregnant within two months
Nursing mothers and pregnant women should not be inoculated, as a ‘precautionary step’
19 December 2020 • 9:30pm
Doctor s visit to a young pregnant woman at home during COVID-19 pandemic
Women who receive the coronavirus jab are being told to abstain from unprotected sex for two months, The Sunday Telegraph can disclose.
Official guidance for healthcare professionals about administering the new Pfizer/BioNTech vaccine says that women of childbearing age should be advised to avoid pregnancy for at least 2 months after their second dose .
The guidance also makes clear that a risk to newborn babies cannot be excluded from the vaccine and so nursing mothers should not be inoculated. It also says that it is unknown whether COVID-19 mRNA Vaccine BNT162b2 has an impact on fertility .